Liraglutide Investigated for Obstructive Sleep Apnoea in Obese Patients

Obesity is a major global health concern, frequently co-occurring with obstructive sleep apnoea (OSA), a condition characterized by repeated breathing interruptions during sleep. OSA can lead to serious cardiovascular and metabolic complications, significantly impacting patient health. While weight loss is known to improve OSA, the direct impact of GLP-1 receptor agonists like liraglutide on OSA severity in obese individuals, independent of weight loss mechanisms, requires further investigation.

The study aimed to quantify the effect of liraglutide on the Apnoea-hypopnoea Index (AHI), a key diagnostic measure for obstructive sleep apnoea severity, which quantifies apnoea and hypopnoea events per hour of sleep. AHI categorizes severity as none (≤4.9 events/hour), mild (5.0-14.9 events/hour), moderate (15.0-29.9 events/hour), or severe (≥30.0 events/hour). While the trial design clearly outlined the measurement of AHI change over 32 weeks, the specific numerical results detailing the observed mean change from baseline in AHI for both the liraglutide and placebo groups were not provided in the available summary. Therefore, a quantitative comparison of treatment versus control regarding AHI improvement cannot be presented here. This means the actual impact of liraglutide on reducing sleep apnoea events in this cohort remains undisclosed in the provided information. The primary outcome was the change in Apnoea-hypopnoea Index (AHI) from baseline after 32 weeks of treatment, a critical metric for assessing obstructive sleep apnoea severity.